For the quarter ending 2026-03-31, ARDT had -$99,909K decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | 58,488 | 74,262 | 1,207 | 154,666 |
| Depreciation and amortization | 42,986 | 41,037 | 39,156 | 75,510 |
| Other non-operating (gains) losses | -3,161 | - | 498 | 777 |
| Other non-operating losses (gains) | - | 1,275 | - | - |
| Loss on extinguishment and modification of debt | - | 0 | -515 | - |
| Amortization of deferred financing costs and debt discounts | 811 | 811 | 1,094 | 2,474 |
| Deferred income taxes | -429 | 28,710 | 17,617 | -2,733 |
| Equity-based compensation | 8,929 | 9,110 | 9,674 | 20,509 |
| Income from non-consolidated affiliates | 8,989 | -366 | -1,547 | 2,956 |
| Accounts receivable | -32 | -42,561 | -30,845 | 14,251 |
| Inventories | 1,245 | -3,160 | 3,190 | 3,118 |
| Prepaid expenses and other current assets | 79,130 | 74,733 | -4,088 | 51,449 |
| Accounts payable and other accrued expenses and liabilities | -14,199 | 77,776 | 34,874 | -50,590 |
| Loss on extinguishment and modification of debt | - | - | - | 0 |
| Accrued salaries and benefits | -65,590 | 20,375 | 16,447 | -36,136 |
| Net cash used in operating activities | -60,222 | 223,435 | 154,372 | 92,703 |
| Investment in acquisitions, net of cash acquired | - | 2,504 | 0 | 0 |
| Purchases of property and equipment | 28,088 | 83,995 | 58,804 | 69,105 |
| Proceeds from divestitures | - | 0 | - | - |
| Other | -187 | -271 | -172 | 264 |
| Net cash used in investing activities | -27,901 | -86,228 | -58,632 | -69,369 |
| Payments of initial public offering costs | - | 0 | 0 | 0 |
| Proceeds from initial public offering, net of underwriting discounts and commissions | - | 0 | 0 | - |
| Debt issuance costs | - | 0 | 2,573 | 0 |
| Proceeds from revolving line of credit | - | 0 | - | - |
| Proceeds from insurance financing arrangements | 17,033 | 0 | 4,648 | 10,959 |
| Proceeds from long-term debt | - | 0 | 0 | 0 |
| Payments of principal on revolving line of credit | - | 0 | - | - |
| Payments of principal on insurance financing arrangements | 2,848 | 4,290 | 4,222 | 6,529 |
| Payments of principal on long-term debt | 3,643 | 3,482 | 1,610 | 2,896 |
| Distributions to noncontrolling interests | 21,314 | 25,873 | 22,841 | 39,525 |
| Redemption of equity attributable to noncontrolling interests | - | 0 | - | - |
| Other | -1,014 | -3,402 | -330 | -1,499 |
| Net cash used in financing activities | -11,786 | -37,047 | -26,928 | -39,490 |
| Net decrease in cash and cash equivalents | -99,909 | 100,160 | 68,812 | -16,156 |
| Cash and cash equivalents at beginning of period | 709,601 | 609,441 | 556,785 | - |
| Cash and cash equivalents at end of period | 609,692 | 709,601 | 609,441 | - |
Ardent Health, Inc. (ARDT)
Ardent Health, Inc. (ARDT)